21 November 2024

Last updated: Monday 18 November 2024

Gene therapy

The role of base and prime editing in therapeutics

Gene-edited therapies produce first clinical data

Gene and cell therapy as a new pillar of medicine

COVID-19's logistical impact on advanced therapies

Solving the viral vector bottleneck during a pandemic

The changing landscape for haemophilia treatment

Meeting the challenge of viral vector manufacture

Human gene therapy - immunogenicity perspective

A bioethical framework for therapeutic gene editing

The precedents set by Zolgensma